根据披露的机构调研信息2025年9月1日至2025年9月26日，泉果基金对上市公司迈威生物进行了调研。 基金市场数据显示，泉果基金成立于2022年2月8日。截至目前，其管理资产规模为161.82亿元，管理基 金数6个，旗下基金经理共5位。旗下最近一年表现最佳的基金产品为泉果旭源三年持有期混合A （016709），近一年收益录得54.74%。 截至2025年9月29日，泉果基金近1年回报前9非货币基金业绩表现如下所示： 基金代码基金简称近一年收益成立时间基金经理016709泉果旭源三年持有期混合A54.742022年10月18日 赵诣 016710泉果旭源三年持有期混合C54.122022年10月18日赵诣 018329泉果思源三年持有期混合 A39.492023年6月2日刚登峰 018330泉果思源三年持有期混合C38.952023年6月2日刚登峰 022223泉果消 费机遇混合发起式A31.762024年9月27日孙伟 019624泉果嘉源三年持有期混合A28.882023年12月5日钱 思佳 019625泉果嘉源三年持有期混合C28.372023年12月5日钱思佳 020855泉果泰然30天持有期债券 A ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Insights - The company reported a 2025 H1 revenue of 101 million yuan, a year-on-year decrease of 12.43%, with a net profit attributable to the parent company of -551 million yuan. However, drug sales revenue reached 100 million yuan, showing a significant year-on-year growth of 53.50%, which is the main growth driver [5][13] - The long-acting G-CSF drug, Mai Li Sheng®, was approved for market release, and a new drug technology license agreement worth 500 million yuan was signed with Qilu Pharmaceutical. Additionally, the company granted CALICO exclusive rights to develop, produce, and commercialize IL-11 targeted therapy products outside Greater China, receiving an upfront payment of 25 million USD, with potential milestone payments up to 571 million USD [5][14] Summary by Sections Financial Performance - In 2025 H1, the company achieved a revenue of 101 million yuan, a decrease of 12.43% year-on-year, while the drug sales revenue was 100 million yuan, increasing by 53.50% [5][13] - The company is expected to see revenues of 677 million, 1.484 billion, and 3.260 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 238.86%, 119.25%, and 119.65% [15][16] Research and Development - The company has increased its R&D expenditure by 21.72% year-on-year, focusing on advancing clinical trials and key registration clinical research phases. As of 2025 H1, the company has 10 innovative drugs and 4 biosimilars in its pipeline, including ADCs and monoclonal antibodies [14] Market Position and Future Outlook - The company is positioned to benefit from the approval of innovative drugs and the gradual market release of biosimilars. The expected net profit attributable to the parent company is projected to improve from -859 million yuan in 2025 to -40 million yuan in 2027 [15][16]

Core Viewpoint - The collaboration between Maiwei Biotech and Calico is noteworthy as it marks a significant shift in the innovation drug landscape, leading to a substantial increase in Maiwei's stock price and market capitalization [2][3]. Company Overview - Maiwei Biotech, established 8 years ago, has gained prominence in the innovative drug sector, with its stock price increasing over 140% this year, reaching a market cap close to 240 billion yuan [2]. - The company has a focus on First-in-Class products, emphasizing deep understanding of biological mechanisms and disease relationships as the foundation for innovation [2][8]. Business Development (BD) Strategy - The partnership with Calico, a leader in anti-aging research, was formed after a swift negotiation process of just five months, highlighting the efficiency of the BD project [3]. - Maiwei's previous BD project involved a collaboration with DISC for a monoclonal antibody targeting TMPRSS6, also a First-in-Class product, indicating a trend of proactive interest from potential partners [4]. Clinical Development and Product Pipeline - Maiwei Biotech has multiple ADCs (Antibody-Drug Conjugates) in clinical trials, with 2025 designated as a key year for BD activities, further fueling market enthusiasm [5]. - The company has maintained a steady pace of product approvals since its listing on the STAR Market in 2022, with significant sales growth reported for its biosimilar products [6]. Market Position and Future Outlook - The company aims to build a comprehensive innovation ecosystem, focusing on First-in-Class and Best-in-Class products, while also exploring unique ADC development strategies [7][9]. - Maiwei's approach to BD emphasizes the importance of understanding target mechanisms and disease relationships, setting it apart from many biotech firms that focus solely on technical iterations [8]. Innovative Sales Strategies - The company is considering a "shared sales" model to enhance efficiency and reduce costs by collaborating with other biotech firms to form a unified sales team [11]. - This strategy reflects a flexible approach to navigating the competitive landscape of the Chinese pharmaceutical market, which is characterized by intense competition and a predominance of generic drugs [10].

Core Viewpoint - The collaboration between Maiwei Biotech and Calico is noteworthy as it marks a significant shift in the innovation drug landscape in China, leading to a substantial increase in Maiwei's stock price and market capitalization [1][2]. Company Overview - Maiwei Biotech, established 8 years ago, has gained prominence in the innovative drug sector, particularly with its IL-11 antibody project, which has First-in-Class potential [1][3]. - The company has experienced a stock price increase of over 140% this year, with its market value reaching nearly 240 billion yuan at one point [1]. Business Development (BD) Strategy - The partnership with Calico, which had not acquired external products for a decade, highlights Maiwei's strategic choice to prioritize collaboration with established players in the anti-aging field [2][3]. - Maiwei's previous BD project involved a collaboration with DISC for a monoclonal antibody targeting TMPRSS6, also a First-in-Class product, indicating a consistent strategy of pursuing innovative drug development [3][6]. Financial Performance - Maiwei's sales revenue has shown significant growth, with a 243.53% increase in sales from its three biosimilar products last year, and a 53.50% increase in sales revenue in the first half of this year [5][6]. - The company anticipates further market penetration for its products, particularly in the context of expanding indications for its drugs [5]. Innovation and Research Focus - Maiwei emphasizes deep research into target mechanisms and disease relationships, which differentiates its approach from many biotech firms that focus on technical iterations [7][8]. - The company is developing multiple ADCs (antibody-drug conjugates) with a focus on tailoring Linkers and Payloads to specific tumor characteristics, aiming for Best-in-Class potential [8][9]. Market Position and Future Outlook - The Chinese pharmaceutical market is characterized by a predominance of generic drugs, which poses challenges for biotech firms; however, Maiwei's strategy includes flexible routes to market through licensing and partnerships [10]. - The company is exploring a "shared sales" model to enhance efficiency and reduce costs by collaborating with other biotech firms to form a unified sales team [10].

Core Viewpoint - The collaboration between Maiwei Biotech and Calico, a leader in anti-aging research, marks a significant shift in the Chinese innovative drug landscape, leading to a substantial increase in Maiwei's stock price and market valuation [4][5][6]. Group 1: Collaboration and Market Impact - Maiwei Biotech's partnership with Calico is noteworthy as it is Calico's first external collaboration in a decade, highlighting the potential of the IL-11 antibody in the anti-aging sector [4][5]. - The collaboration has resulted in a stock price increase of over 140% for Maiwei Biotech this year, with a market capitalization nearing 24 billion yuan [4][5]. - The rapid negotiation process, taking only five months from initial contact to contract signing, exemplifies the efficiency of the deal [5][6]. Group 2: Product Development and Strategy - Maiwei Biotech has a history of pursuing First-in-Class products, with the IL-11 antibody being the first to reach a BD project, contrary to initial expectations [4][6][14]. - The company has also engaged in other BD projects, including a collaboration with DISC for a TMPRSS6 monoclonal antibody, which is also a First-in-Class product [6][14]. - The focus on First-in-Class products stems from a deep understanding of biological mechanisms and disease relationships, differentiating Maiwei from other biotech firms [14][15]. Group 3: Financial Performance and Growth - The sales revenue for Maiwei Biotech's biosimilar products has shown significant growth, with a year-on-year increase of 243.53% for three products last year and a 53.50% increase in the first half of this year [10][10]. - The company anticipates further market penetration for its products, with plans for additional approvals that could significantly increase patient numbers [10][10]. - The strategic decision to develop both innovative drugs and biosimilars has allowed the company to maintain a steady revenue stream while pursuing long-term innovation [10][10]. Group 4: Industry Positioning and Future Outlook - Maiwei Biotech aims to position itself as a pharmaceutical company rather than just a biotech firm, focusing on controlling the entire product lifecycle from development to sales [16][17]. - The company is exploring innovative sales models, such as shared sales teams among multiple biotech firms, to enhance efficiency and reduce costs [18][18]. - With a robust pipeline of First-in-Class and Best-in-Class candidates, Maiwei is well-positioned to capitalize on emerging opportunities in the innovative drug market [15][15].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - 9MW3811, an IL-11 monoclonal antibody developed by the company, is leading globally in clinical progress and has received clinical access in China, the US, and Australia, with completed Phase I trials showing good safety [2][17] - The company has licensed global development and commercialization rights for 9MW3811 (excluding Greater China) to Calico Life Sciences, receiving a non-refundable upfront payment of $25 million and potential milestone payments up to $571 million [2][36] - The market potential for treating pathological scars, including hypertrophic scars and keloids, is significant, with the US market projected to grow from $10.3 billion in 2020 to $12.3 billion in 2025, and further to $18.6 billion by 2030 [40][44] Summary by Sections 1. 9MW3811: Targeting Fibrosis and Aging - 9MW3811 effectively blocks the IL-11/IL-11Ra signaling pathway, addressing unmet needs in fibrosis and aging [2][3] - The mechanism of action for 9MW3811 is well-defined, targeting key aging markers and potentially improving metabolic function and chronic inflammation [3][18] - The product is positioned to address the urgent clinical needs in the pathological scar market, with a projected market size of $5.9 billion in China by 2030 [3][40] 2. Multiple Promising Pipeline Products - 9MW1911, a ST2 monoclonal antibody for COPD, is in Phase Ib/IIa trials with all 80 patients enrolled, aiming for efficacy data by the end of 2025 [4][49] - 9MW2821, a Nectin-4 ADC, is leading globally in clinical progress with promising efficacy data across multiple cancer types, including bladder and triple-negative breast cancer [4][55] - The company is developing additional ADCs and TCE platforms, enhancing its pipeline diversity and potential market impact [4][49] 3. Earnings Forecast and Investment Rating - The revenue forecast for 2025-2027 is maintained at approximately $1.11 billion, $1.24 billion, and $2.09 billion respectively, excluding unrecognized business development payments [5] - The report emphasizes the strong potential of the company's pipeline and maintains a "Buy" rating based on these projections [5]

Group 1 - The stock price of Maiwei Biotech-U is reported at 33.09 yuan, down by 0.71 yuan from the previous trading day, with a trading volume of 4.27 billion yuan [1] - Maiwei Biotech-U operates in the biopharmaceutical industry, focusing on the research, production, and sales of antibody drugs, including monoclonal antibodies and bispecific antibody drugs [1] - The company announced the completion of the first patient dosing in the clinical trial of its innovative drug 9MW2821 targeting Nectin-4ADC for patients with ADC-treated triple-negative breast cancer in the United States, marking its first overseas clinical trial [1] Group 2 - On August 12, the net outflow of main funds was 46.4564 million yuan, with a cumulative net outflow of 218 million yuan over the past five days [1]

Core Insights - Business Development (BD) transactions are becoming a crucial pathway for Chinese innovative pharmaceutical companies to advance globalization, with over 40% of significant upfront payments from multinational corporations (MNCs) originating from China in the first half of 2025 [1] - Maiwei Biotech has made substantial progress in BD transactions, reflecting its transition from "generic innovation" to "global innovation" [1][4] Group 1: BD Transactions - Maiwei Biotech recently entered into a collaboration with Calico Life Sciences, receiving a non-refundable upfront payment of $25 million for global rights to develop, produce, and commercialize the IL-11 monoclonal antibody 9MW3811 outside Greater China [2] - The agreement with Calico includes potential milestone payments of up to $571 million and tiered royalties based on global sales, indicating significant long-term revenue potential [2] - Additionally, Maiwei Biotech signed an agreement with Qilu Pharmaceutical for exclusive rights to develop, produce, and commercialize injectable Agonist α in Greater China, with a maximum upfront payment of 500 million RMB and sales milestone payments [3] Group 2: Revenue and Financial Impact - The two BD transactions are expected to generate at least 650 million RMB in short-term revenue, alleviating financial pressure and supporting the development of innovative drug pipelines [3] - The collaborations enhance the company's revenue sources and provide a solid foundation for its domestic market strategy [3] Group 3: R&D and Pipeline Development - Maiwei Biotech has established a comprehensive R&D system that supports its BD activities, with a pipeline consisting of 16 products, including 12 innovative drugs and 4 biosimilars [4] - The company focuses on oncology and age-related diseases, with several ADC pipelines and a strong presence in various therapeutic areas [4][6] - The innovative drug-centric pipeline structure allows for immediate commercialization cash flow while reserving long-term growth potential through innovative drug development [4] Group 4: Technological Platforms - The company has developed four major technological platforms, including specialized platforms for ADCs and bispecific antibodies, which enhance its R&D capabilities [5][6] - The integration of these platforms fosters sustainable innovation and positions the company as an attractive partner for collaborations [6] Group 5: Future Prospects - Maiwei Biotech aims to achieve significant breakthroughs in its BD business by 2025, with ongoing collaborations on key pipelines such as Nectin-4ADC and B7-H3ADC [6] - The company is recognized for its early investments in ADCs, with promising clinical developments for its products, including 9MW2821, which is leading in clinical trials for cervical cancer [6][7]

Core Viewpoint - The company has announced an adjustment to its share repurchase plan, increasing the maximum repurchase price from RMB 35.00 per share to RMB 48.00 per share to ensure the smooth implementation of the plan [7][11][17]. Group 1: Share Repurchase Plan Overview - The company approved a share repurchase plan on June 26, 2025, allowing for the repurchase of its A-shares using self-owned funds and/or special loans, with a total repurchase amount between RMB 25 million and RMB 50 million [1][9]. - The repurchase period is set for 12 months from the date of board approval [1][9]. - As of July 31, 2025, the company has not yet implemented the share repurchase [2][10]. Group 2: Adjustment of Repurchase Price - The maximum repurchase price has been adjusted to RMB 48.00 per share due to the company's stock price exceeding the previous limit, which limited the implementation window [11][15]. - The adjustment is based on the company's confidence in its future development and aims to protect shareholder interests [11][16]. - The total repurchase amount remains unchanged, and the repurchase plan's other details are not affected by this adjustment [16][17]. Group 3: Company’s Business and Market Position - The company focuses on oncology and age-related diseases, with 16 core products in various stages of development, including 12 innovative drugs and 4 biosimilars [12]. - The company has several innovative drugs in critical clinical research stages, with notable achievements such as receiving multiple designations from the FDA for its drug 9MW2821 [12]. - The company has established international partnerships and is expanding its market presence, particularly in emerging markets along the Belt and Road Initiative [13].

Core Viewpoint - The company, Maiwei (Shanghai) Biotechnology Co., Ltd., has announced an adjustment to the upper limit of its share repurchase price from RMB 35.00 per share to RMB 48.00 per share to ensure the smooth implementation of its share repurchase plan [1][2][7] Summary of Share Repurchase Plan - The company plans to repurchase its issued A-shares through centralized bidding on the Shanghai Stock Exchange, with a total repurchase fund not less than RMB 25 million and not exceeding RMB 50 million [1][6] - The repurchase period is set for 12 months from the date of the board's approval of the repurchase plan [1] Reasons for Adjustment - The adjustment to the repurchase price limit is due to the recent continuous rise in the company's stock price, reflecting confidence in the company's future stable development and recognition of its value [2][5] - The new upper limit of RMB 48.00 per share is based on the company's comprehensive consideration of market conditions and the progress of the share repurchase [6][7] Company’s Product Pipeline - The company has a robust pipeline with 16 core products in various stages, including 12 innovative drugs and 4 biosimilars, with 4 already on the market [2][3] - Notable products include 9MW2821, which has received multiple designations from the FDA, and other innovative monoclonal antibodies with significant potential in treating various diseases [3][4] Financial Performance - The company reported a sales revenue of RMB 139 million for its product Deshu Single Antibody in 2024, marking a year-on-year increase of 230.17% [4] - The company has signed licensing agreements with other pharmaceutical companies, which include substantial upfront payments and potential royalties based on sales [5] Decision-Making Process - The adjustment to the repurchase price limit was approved in a board meeting held on August 5, 2025, and does not require shareholder approval [7]